UY39574A - Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene - Google Patents

Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene

Info

Publication number
UY39574A
UY39574A UY0001039574A UY39574A UY39574A UY 39574 A UY39574 A UY 39574A UY 0001039574 A UY0001039574 A UY 0001039574A UY 39574 A UY39574 A UY 39574A UY 39574 A UY39574 A UY 39574A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
composition containing
treat cancer
compound useful
macrocyclic compound
Prior art date
Application number
UY0001039574A
Other languages
English (en)
Spanish (es)
Inventor
Jingrong J Cui
Eugene Rui
Evan W Rogers
Original Assignee
Blossomhill Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blossomhill Therapeutics Inc filed Critical Blossomhill Therapeutics Inc
Publication of UY39574A publication Critical patent/UY39574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
UY0001039574A 2020-12-17 2021-12-17 Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene UY39574A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063126722P 2020-12-17 2020-12-17
US202163279850P 2021-11-16 2021-11-16
US202163284789P 2021-12-01 2021-12-01
US202163289014P 2021-12-13 2021-12-13

Publications (1)

Publication Number Publication Date
UY39574A true UY39574A (es) 2022-07-29

Family

ID=82058646

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039574A UY39574A (es) 2020-12-17 2021-12-17 Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene

Country Status (12)

Country Link
US (1) US20240182487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4262796A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553835A (cg-RX-API-DMAC7.html)
KR (1) KR20230121773A (cg-RX-API-DMAC7.html)
AU (1) AU2021401741A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202770A1 (cg-RX-API-DMAC7.html)
IL (1) IL303419A (cg-RX-API-DMAC7.html)
MX (1) MX2023007162A (cg-RX-API-DMAC7.html)
PY (1) PY21110949A (cg-RX-API-DMAC7.html)
TW (1) TWI923651B (cg-RX-API-DMAC7.html)
UY (1) UY39574A (cg-RX-API-DMAC7.html)
WO (1) WO2022133037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250022117A (ko) * 2022-06-08 2025-02-14 블로썸힐 테라퓨틱스, 인크. 인다졸 거대고리 화합물 및 그의 용도
AU2023282906A1 (en) * 2022-06-08 2024-11-28 Blossomhill Therapeutics, Inc. Indazole containing macrocycles and their use
CN119013283A (zh) * 2022-07-27 2024-11-22 上海和誉生物医药科技有限公司 大环egfr抑制剂及其制备方法和药学上的应用
JP2026507655A (ja) * 2023-02-22 2026-03-04 ユーハン・コーポレイション Egfr阻害剤としての大環状アミノピリジン化合物
JP2026507653A (ja) * 2023-02-22 2026-03-04 ユーハン・コーポレイション Egfr阻害剤としての大環状アミノピリジン化合物
CN120981466A (zh) * 2023-02-22 2025-11-18 柳韩洋行 作为egfr抑制剂的大环氨基吡啶化合物
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
JP2026517554A (ja) * 2023-05-02 2026-06-02 ブロッサムヒル・セラピューティクス・インコーポレイテッド 疾患の処置のためのegfr阻害剤
JP2026521264A (ja) * 2023-06-23 2026-06-29 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状インダゾール化合物の併用療法
TW202527935A (zh) * 2023-12-07 2025-07-16 美商榮山醫藥股份有限公司 吲唑巨環多晶型物
IL328856A (en) * 2023-12-08 2026-08-01 Blossomhill Therapeutics Inc Indazole-based macrocyclic compounds
WO2025199438A1 (en) * 2024-03-22 2025-09-25 Blossomhill Therapeutics, Inc. 7-azaindazole macrocycles and their use
WO2025245175A1 (en) * 2024-05-22 2025-11-27 Ajax Therapeutics, Inc. Macrocyclic heteroaromatic inhibitors of jak2
WO2026064346A1 (en) * 2024-09-18 2026-03-26 Blossomhill Therapeutics, Inc. Tetracyclic-macrocycles and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
EP3333157B1 (en) * 2015-08-07 2020-12-23 Harbin Zhenbao Pharmaceutical Co., Ltd. Vinyl compounds as fgfr and vegfr inhibitors
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
IL317393A (en) * 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses

Also Published As

Publication number Publication date
PY21110949A (es) 2023-08-07
TW202241911A (zh) 2022-11-01
WO2022133037A1 (en) 2022-06-23
EP4262796A1 (en) 2023-10-25
IL303419A (en) 2023-08-01
JP2023553835A (ja) 2023-12-26
MX2023007162A (es) 2023-06-29
TWI923651B (zh) 2026-05-01
EP4262796A4 (en) 2025-04-02
US20240182487A1 (en) 2024-06-06
KR20230121773A (ko) 2023-08-21
CA3202770A1 (en) 2022-06-23
AU2021401741A9 (en) 2024-09-19
AU2021401741A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2023007162A (es) Macrociclos y sus usos.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
DOP2018000222A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer antecedentes
UY39779A (es) Compuestos macrocíclicos para tratar enfermedades
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
UY36702A (es) Piridinas sustituidas y métodos de uso
CO6710897A2 (es) Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer
MX381235B (es) Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer.
CL2023000061A1 (es) Macrociclos y su uso
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CO2022014837A2 (es) Células t v delta1+ para el tratamiento de neoplasias mieloides
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CR20240533A (es) Macrociclos de indazol y su uso
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
DOP2025000274A (es) Inhibidores de egfr para el tratamiento de enfermedades
CL2022002527A1 (es) Células t v delta1 para el tratamiento de neoplasias mieloides